ATP-Long 20 mg tablets No. 40

ATP-Long (ATP-LONG) instruction manual

Composition

active ingredients: 1 tablet contains ATP-LONG (in terms of a substance that does not contain sodium chloride and water) - 20 mg with the content of adenine nucleotides 12,6 mg
auxiliary substances: powdered sugar; lactose; magnesium stearate silicon dioxide colloidal.

Dosage form

Pills.

Basic physical and chemical properties:

tablets of 20 mg of white color with a flat surface, bevel and risk.

Pharmacological group

Cardiological preparations. Code ATX C01E B10.

Pharmacological properties

Pharmacodynamics.

ATP-long is a preparation of a new class of substances - different ligand coordination compounds with macroergic phosphates, the molecule of which consists of adenosine-5-triphosphate (ATP), amino acids of histidine, magnesium and potassium salts, and has a characteristic pharmacological effect only for it, chemical component (ATP, histidine, K +, Mg + +).

ATP-long affects metabolic processes in the myocardium, normalizes the energy metabolism, the activity of ion transport systems of cell membranes, the lipid composition of membranes, the activity of membrane-bound enzymes, improves the antioxidant system of myocardial defense, has anti-ischemic, membrane-stabilizing effect, antiarrhythmic effect in supraventical tachycardia.

The drug has an energy-saving effect due to inhibition of the activity of the 5'-nucleotidase enzyme, which is responsible for the rate of hydrolysis of energy substrates. ATP-LONG prevents structural and functional damage to plasmatic membranes of cardiomyocytes, ensuring the preservation of the quantitative and qualitative composition of membrane lipids, inhibiting the activity of membrane-bound phospholipases. ATP-LONG suppresses the intensity of the processes of lipid peroxidation (LPO), thereby reducing the accumulation in the membranes of products of hydrolysis and peroxidation of phospholipids of fatty acids, lysophospholipids, which are characterized by pronounced detergent properties and the ability to cause contractile and rhythmic heart failure in ischemia. In the case of experimental myocardial ischemia, the drug increases the activity of Na + - K + - ATPase and Ca 2+, Mg 2+ - ATPase and the calcium binding potential of the membrane.

ATP-long improves the indices of central and peripheral hemodynamics, coronary circulation, normalizes myocardial contractility, which leads to an increase in the indices of physical working capacity. In conditions of ischemia, the drug reduces myocardial oxygen consumption, activates the functional state of the heart, increases cardiac output, which leads to a decrease in the frequency of angina attacks and shortness of breath during physical exertion.

ATP-long restores the normal sinus rhythm in patients with paroxysmal supraventricular tachycardia, with flashing and fluttering of the atria, and also reduces the activity of ectopic foci of rhythm (atrial and ventricular extrasystoles).

ATP-long normalizes the concentration of potassium and magnesium in tissues, reduces the concentration of uric acid.

Pharmacokinetics.

When administered to the body, ATP-long slowly decays with the formation of adenosine.

Indications

Complex therapy:

• ischemic heart disease, unstable angina, restless stenocardia and tension;
• postinfarction and myocarditis cardiosclerosis (diffuse and focal cardiosclerosis)
• disorders of the heart rhythm;
• neurocirculatory dystonia;
• myocardiodystrophy;
• myocarditis;
• chronic fatigue syndrome.

Contraindications

• Hypersensitivity to the drug and its components;
• acute myocardial infarction;
• cardiogenic and other types of shock;
• obstructive diseases of bronchopulmonary system;
• severe forms of bronchial asthma
• sinoatrial block
• blockade II-III degree;
• hyperkalemia, hypermagnesia;
• hemorrhagic stroke.

Interaction with other drugs and other types of interactions.

ATP-long can not be used simultaneously with cardiac glycosides due to an increased risk of AV blockade.

With simultaneous reception with potassium-sparing diuretics, potassium preparations and ACE inhibitors, the risk of hyperkalaemia, with magnerot and other magnesium preparations - hypermagnesemia, increases.

Dipyridamole enhances the therapeutic effect of ATP-long in, and xanthinal nicotinate, caffeine, theophylline, aminophylline-reduce.

ATP-long can strengthen the antianginal effect of alpha and beta-blockers, calcium channel blockers, nitrates.

application features

Use with caution in severe arterial hypotension; simultaneously with cardiac glycosides in connection with an increased risk of AV blockade, with a tendency to bronchospasm.

With prolonged use it is necessary to monitor the level of potassium and magnesium in the blood.

The composition of the drug includes powdered sugar and lactose, so patients with diabetes should use the drug with caution. Patients with hereditary intolerance to glucose-galactose, sucrose-isomaltose drug should not be used. Limit the use of products that include caffeine (coffee, tea, drinks with cola).

Use during pregnancy and lactation

Clinical data on the safety and efficacy of the drug during pregnancy are not available, so the use of it in pregnant women is contraindicated. For the period of treatment, breast-feeding should be discontinued.

The ability to influence the reaction rate when driving vehicles or other mechanisms.

If during dasg treatment, dizziness, lowering of blood pressure, abstain from driving and working with other mechanisms.

Dosing and Administration

Tablets ATP-long take under the tongue (sublingually) and keep until complete resorption. Single dose - 10 * -40 mg 3-4 times a day, regardless of food intake.

In acute heart conditions (attack of angina pectoris, arrhythmia) ATP-long tablets take 10 * -80 mg until the condition improves. The maximum daily dose is 160 mg.

Term of treatment is determined by a doctor, on average, it is 20-30 days. If necessary, repeat the course in 10-15 days.

(* Use in the appropriate dosage)

Children

Do not use it for children.

Overdose

Symptoms: possible development of bradycardia, AV blockade, arterial hypotension, syncope, associated with a sudden drop in blood pressure.

Treatment: stop taking the drug and begin symptomatic therapy. With bradycardia, enter atropine sulfate.

Adverse Reactions

From the skin and subcutaneous tissue: skin rashes, itching, flushing of the face, swelling of Quincke.

From the respiratory system: bronchospasm.

From the cardiovascular system: lowering blood pressure, tachycardia, blockade.

From the gastrointestinal tract: nausea, a feeling of discomfort in the epigastric region, increased motility of the digestive tract.

From the urinary system: increased diuresis.

From the nervous system: headache, dizziness.

From the side of the vessels: a feeling of heat.

From the side of the immune system: allergic reactions, incl. skin rashes, itching, swelling of the Quincke.

Shelf life

3 years. The drug should not be used after the expiry date indicated on the package.

Storage conditions

Store in the original packaging at a temperature not exceeding 5 ° C. Store in a place inaccessible to children.

Packaging

For 10 tablets in a blister, 3 or 4 blisters in a box labeled in Russian and Ukrainian.

Category of leave

Without recipe.